The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
